Our Science

The unmet needs in dermatology demand differentiated thinking.

We have the technical expertise to develop and commercialize unique products

VYNE Therapeutics™ is applying technical expertise to identify ways to challenge the status quo about how medicines can work – and may work better. We’re the foremost experts in dermatologic medicine innovation, but we’re not stopping there. This expertise is a springboard for our approach to dermatology innovation, and beyond.

For example, we approach foam as not just a formulation, but a technology that can be engineered, refined, and elevated. That mindset was the key to clearing technical hurdles that no one else has yet overcome.

Our signature technological achievement is our proprietary Molecule Stabilizing Technology (MST™). This breakthrough allows for localized delivery of therapeutic agents that were not previously stable in topical formulations.

VYNE has developed the first foam that works without surfactants – using instead natural oils that work with, rather than against, the natural moisturizing oils of human skin. We are seeing just the beginning of the possible advantages of foam, like enhanced usability, improved tolerability, and targeted delivery of therapeutic agents.

With topical minocycline as proof that the technology works, the MST™ platform provides the opportunity to develop additional topical products delivering proven therapeutic agents.

We anticipate that the same engineering mindset that drove our breakthroughs in foam technology and topical medicines will lead to continued breakthroughs in innovation and R&D.

The potential advantages of MST™:

  • Unique hydrophobic foam helps medicine be easily applied directly to the skin
  • Proprietary delivery system has the potential to stabilize medicines for topical application that were previously hard-to-deliver topically
  • Free of primary irritants

The promise of MST™ is fueling our pipeline.

MST™ has already made two products possible and is playing a role in our other investigational new drug candidates.


The safety and efficacy of these products has not been established. There is no guarantee that these products will receive health authority approval or become commercially available.